NBPNasdaqPharmaceutical PreparationsFiscal year ends December 31

NovaBridge Biosciences

Financials through fiscal 2025, year ended Dec 31, 2025Last filing: 20-F on Apr 7, 2026

$1.30+0.04 (+3.17%)

Close on Oct 19, 2026

NovaBridge Biosciences cash flow statement

Annual Quarterly TTM

CNY USD

Millions of CNY, except per-share data. Shares in millions.

Line item	TTM FY 2020 2020-12-31	TTM FY 2019 2019-12-31
Depreciation & Amortization	13	9.80
Stock-Based Compensation	493	367
Change in Accounts Payable	174	188
Operating Cash Flow	434	-868
Capital Expenditures	-8.01	-12
Purchase of Investments	-2,492	-134
Sale & Maturity of Investments	2,504	359
Investing Cash Flow	-202	212
Share Repurchases	-35	–
Financing Cash Flow	3,440	153
Foreign Exchange Rate Adjustments	-107	15
Net Change in Cash	3,565	-488
Free Cash Flow	426	-880
Interest Paid	0.96	2.99

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Dec 31, 2025

Profitability, FY

Gross margin: –
Operating margin: –
Net margin: –
Return on equity, FY2025: –

Financial strength

Current ratio: –
Debt to equity: –
Debt to assets: –
Cash to current liabilities: –

Valuation

P/E ratio: –
Price to sales: –
Price to book: –
Dividend yield: –

Valuation ratios need the share price and fill in once daily prices are connected.